Journal article

Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression

Sherly Mardiana, Benjamin J Solomon, Phillip K Darcy, Paul A Beavis

SCIENCE TRANSLATIONAL MEDICINE | AMER ASSOC ADVANCEMENT SCIENCE | Published : 2019

Abstract

The development of new cancer immunotherapies including checkpoint blockade and chimeric antigen receptor (CAR) T cell therapy has revolutionized cancer treatment. CAR T cells have shown tremendous success in certain B cell malignancies, resulting in U.S. Food and Drug Administration (FDA) approval of this approach for certain types of leukemia and lymphoma. However, response rates against solid cancer have been less successful to date. Approaches to modulate the immunosuppressive tumor microenvironment including targeting checkpoint pathways, modulating metabolic pathways, and generating cytokine-producing T cells have led to considerable enhancement of adoptive T cell immunotherapy, first ..

View full abstract

Grants

Awarded by National Health and Medical Research Council (NHMRC)


Awarded by Cancer Council Victoria project grant


Awarded by National Breast Cancer Foundation Fellowship


Awarded by NHMRC Senior Research Fellowship


Funding Acknowledgements

This work was funded by a program grant from the National Health and Medical Research Council (NHMRC; APP1132373) and a Cancer Council Victoria project grant (APP1143517). P.A.B. is supported by a National Breast Cancer Foundation Fellowship (ID #ECF-17-005). P.K.D. is supported by an NHMRC Senior Research Fellowship (APP1136680).